Newsletter
“Site archetype” tells us how many referrals to initially send to a site. How a site actually acts on its first two months of referrals tells us how to update.
Newsletter
Not every enrollment slowdown is a site problem. Sometimes it's a portfolio problem. Here's how to tell the difference and what to do about it.
Newsletter
Your local call center knows exactly how every agent performed today. Your clinical trial sites? They're still filling out spreadsheets.
Newsletter
"The last paragraph in a paper is often what you really want to be doing,"
Newsletter
In 1996, a young psychiatrist named Joseph Palumbo joined Cephalon to work on myotrophin, a promising ALS candidate. It didn't succeed. What he learned shaped the first ALS approval in over 20 years.
Newsletter
How "positive deviance" can help you find what's working and scale it
Newsletter
The operational insights behind our biggest year in patient recruitment
Newsletter
How a time-constrained 6-month proof-of-concept study and disciplined trial methodology transformed a shelved compound into a $14 billion breakthrough
Newsletter
Why patients who seem "engaged" disappear... and what site behaviors may be driving them away
Newsletter
The AtaiBeckley merger reflects a bet that shorter treatment durations will improve patient access and payer acceptance.
Newsletter
An engineer's path from NASDAQ IPO to hemp-derived THC trials reveals the operational realities many clin ops teams don't discuss.
Newsletter
How Karuna's former CMO turned disciplined trial methodology into a $14 billion BMS acquisition